CYP 2.50% 19.5¢ cynata therapeutics limited

Ann: Cynata Enters into a New Strategic Partnership with Fujifilm, page-3

  1. 15,592 Posts.
    lightbulb Created with Sketch. 5665
    ... this is disappointing - no wonder they haven't done anything in a couple of years ?


    Cynata has regained rights to CYP-001 for graft-vs-host-disease (“GvHD” and Fujifilm will pay Cynata US$5m under the September 2019 licence agreement. The licence agreement has been terminated and Cynata will immediately implement a US development strategy for CYP-001 to capitalize on the unmet need and market opportunity for an effective and scalable MSC therapeutic for GvHD in the US market, for which it has already secured Orphan Drug Designation.
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
19.5¢
Change
-0.005(2.50%)
Mkt cap ! $35.20M
Open High Low Value Volume
20.0¢ 20.0¢ 19.5¢ $1.705K 8.654K

Buyers (Bids)

No. Vol. Price($)
3 12792 19.5¢
 

Sellers (Offers)

Price($) Vol. No.
20.0¢ 32500 1
View Market Depth
Last trade - 10.02am 30/08/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.